Life Technologies has acquired University of Michigan spin-out
Compendia Bioscience.
Suzanne Clancy, a spokeswoman for
Life Technologies, confirms the Ann Arbor-based start-up will remain in Ann Arbor for the foreseeable future and under its current leadership. The terms of the deal were not disclosed, and Clancy declined to speak about Compendia Bioscience's current employment levels.
Compendia Bioscience specializes in cancer bioinformatics, which is used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. The California-based Life Technologies, a public company listed on the NASDAQ, plans to leverage Compendia BioScience's oncology expertise and proprietary assets to enhance its diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and proteome analysis.
Compendia Bioscience spun out of the University of Michigan in 2006 and has been led by Daniel Rhodes ever since. It received $1.75 million from the Michigan 21st Century Jobs Fund in 2008. It had as many as 30 employees as of 2011, according to the company's website.
Source: Suzanne Clancy, spokeswoman for Life Technologies
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.